Rapport Therapeutics Inc
NASDAQ:RAPP

Watchlist Manager
Rapport Therapeutics Inc Logo
Rapport Therapeutics Inc
NASDAQ:RAPP
Watchlist
Price: 27.92 USD 5.76%
Market Cap: $1.3B

Gross Margin

0%
Current
No historical data
Comparison unavailable

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
0%
=
$0
/
$0

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Gross
Margin
US
Rapport Therapeutics Inc
NASDAQ:RAPP
1.3B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
220.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.2B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.4B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Rapport Therapeutics Inc
Glance View

Market Cap
1.3B USD
Industry
Pharmaceuticals

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The company is headquartered in Boston, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2024-06-07. The firm focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. The company advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.

RAPP Intrinsic Value
6.41 USD
Overvaluation 77%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Back to Top